Natera price target raised to $80 from $70 at Piper Sandler

Piper Sandler analyst David Westenberg raised the firm’s price target on Natera to $80 from $70 and keeps an Overweight rating on the shares after the company received a Centers for Medicare and Medicaid Services decision stating the agency will cover Signatera for most Medicare breast cancer patients. The analyst thinks this could add $30M in revenue to Signatera and help offset the reproductive health headwinds into the print. Piper estimates more than 80% of Signatera volumes are in a covered indication, which should help drive the selling price up quickly in 2023.